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Abstract: The long-term use of inhaled anticholinergic agents has recently been suggested 
to be associated with an excess risk of adverse cardiovascular (CV) outcomes in patients with 
COPD. We identified 15 published studies that reported on the association between long-term 
inhaled anticholinergic use and adverse CV outcomes. Only 3 of the studies were adequately 
designed randomized controlled trials (RCTs). The first RCT that suggested that anticholinergic 
agents increased the risk of adverse CV outcomes was the Lung Health Study (LHS). Smokers 
randomized to inhaled ipratropium had a significantly increased risk of CV death than smokers 
receiving placebo. The LHS results have been questioned as the statistical tests used in the 
study were not adjusted for multiple tests and endpoints, a convincing dose-effect relationship 
between ipratropium use and the adverse CV outcomes was not established, and most of the CV 
deaths in the ipratropium group occurred in patients who were non-compliant to ipratropium. 
The Investigating New Standards for Prophylaxis in Reducing Exacerbations (INSPIRE) was a 
RCT that compared the combination of salmeterol plus fluticasone against tiotropium in patients 
with COPD. All-cause mortality was significantly lower in the salmeterol plus fluticasone group 
(3%) compared to the tiotropium group (6%). Fatal CV events occurred in 1% of the salmeterol 
plus fluticasone group compared to 3% in the tiotropium group. The INSPIRE trial was not 
designed to be a mortality trial, lacked adequate adjudication of fatal outcomes, and lacked a 
full intention-to-treat analysis of the data. The Understanding Potential Long-Term Impacts 
on Function with Tiotropium (UPLIFT) trial was a RCT comparing tiotropium and placebo in 
patients with COPD. Follow-up in UPLIFT was planned for 1440 days (4 years) plus 30 days 
(1470 days) of post-treatment follow-up. At 1440 days with 95% of patient outcome accounted 
for, tiotropium was associated with a significant 13% reduction in all-cause mortality compared 
to placebo. However, at 1470 days with only 75% of patient outcome accounted for, tiotro-
pium was associated with a non-significant 11% reduction in all-cause mortality compared to 
placebo. The relative risks for serious CV events, heart failure, and myocardial infarction were 
all significantly lower with tiotropium than placebo. It is not certain why such a wide disparity 
in findings exists among the published studies evaluating the CV risks of inhaled anticholinergic 
agents. Prospective, adequately powered RCTs are needed to provide more evidence for the 
CV safety of tiotropium.
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Evidence-based treatment guidelines
Evidence-based guidelines for the management of chronic obstructive pulmonary 
disease (COPD) were first developed by the National Heart, Lung, and Blood Institute 
and the World Health Organization, the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD).1 Since then, the GOLD has been updated and revised and additional International Journal of COPD 2009:4 254
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guidelines have been published by the American Thoracic 
Society, the European Respiratory Society, the Canadian 
Thoracic Society, and the National Institute for Clinical 
Excellence with the purpose of improving the prevention, 
diagnosis, and management of COPD.2–5
The goals of treatment in patients with COPD are to 
relieve symptoms, prevent disease progression, reduce the 
frequency and severity of exacerbations, improve health status, 
improve exercise tolerance, and reduce mortality. Ideally, 
these therapeutic goals should be realized with minimal 
side effects from treatment, a difficult challenge in COPD 
patients because of their high incidence of comorbidities. All 
of the guidelines agree that bronchodilators are a mainstay of 
therapy for patients with COPD. Currently available bron-
chodilators include beta-2 agonists, anticholinergics, and 
methylxanthines. Short-acting bronchodilators are recom-
mended for relief of symptoms on an as needed basis while 
long-acting bronchodilators are recommended to be given 
on a regularly scheduled basis for persistent symptoms. 
Inhaled bronchodilators are also generally preferred over 
oral agents in order to minimize systemic exposure and 
side effects. Hence, the initial selection of a long-acting 
bronchodilator typically includes a beta-2 agonist or an 
anticholinergic rather than a methylxanthine. The guidelines 
do not specify which type of bronchodilator is preferred for 
the initial management of COPD. The use of combinations 
of bronchodilators is recommended for patients with persis-
tent symptoms not controlled following the use of a single 
bronchodilator. As a result, many patients are receiving both 
beta-2 agonists and anticholinergics. In patients with severe 
COPD experiencing frequent exacerbations despite the use 
of one or more bronchodilators, the addition of inhaled 
corticosteroids is recommended.
In March 2008, the FDA issued an “early warning” 
communication which stated that Boehringer Ingelheim (the 
manufacturer of tiotropium) had conducted a pooled analysis 
of 29 trials which found an increased risk of stroke with 
tiotropium (8 cases per 1000) compared to placebo (6 cases 
per 1000).6 In September 2008, a meta-analysis published in 
JAMA reported a significantly increased risk of cardiovas-
cular mortality with inhaled anticholinergics.7 The results of 
this meta-analysis and the “early warning” communication 
from the FDA has raised concerns about the routine use of 
inhaled anticholinergic agents in patients with COPD.
The purpose of this systematic review is to evaluate 
the currently available evidence concerning the efficacy 
and safety of the long-term use of inhaled anticholinergic 
agents in patients with COPD. All clinical studies of inhaled 
anticholinergic agents in patients with COPD were identified 
through a computerized literature search using the following 
databases: PubMed 1950–2009; Ebsco Host 1950–2009; 
and The Cochrane Central Register of Controlled Trials 
1996–2009 in the Cochrane Library. The key terms used 
included ipratropium, tiotropium, formoterol, salmeterol, 
inhaled corticosteroids, cardiovascular events, morbidity, 
mortality, and COPD. Identified studies were evaluated and 
grouped according to their conclusions on the relationship 
between inhaled anticholinergic agents and adverse cardio-
vascular outcomes.
Evidence that anticholinergics 
increase adverse cardiovascular 
outcomes
Singh et al performed a meta-analysis designed to evaluate 
the risk of major adverse cardiovascular events with inhaled 
anticholinergic agents in patients with COPD.7 Trials were 
included if they were randomized and controlled using any 
inhaled anticholinergic agent (ipratropium or tiotropium) 
with 30 days or more of follow-up. Study participants could 
have a COPD diagnosis of any severity. Trials including 
patients with asthma were excluded. The control group could 
include placebo or an active control (inhaled beta-agonist or 
inhaled beta-agonist combination). The trials had to report 
the incidence of serious cardiovascular events including 
myocardial infarction, stroke and cardiovascular death.
A total of 103 trials were reviewed in detail with 17 
(12 with tiotropium and 5 with ipratropium) trials meeting 
the inclusion criteria. Of the 86 trials excluded from the 
analysis, 69 were excluded as they did not report adverse 
cardiovascular events, two trials reported a zero incidence 
of events in both treatment groups, and 15 were not random-
ized, controlled trials of anticholinergic versus control lasting 
longer than 30 days.
In the 17 trials, a total of 14,783 patients were included 
in which 7472 received an anticholinergic agent and 7311 
received a control therapy. Nine trials compared inhaled 
anticholinergics with placebo and 8 included an active 
comparison (salmeterol in 6 trials, salmeterol/fluticasone 
in trial and albuterol in 1 trial). Five trials were long-term 
(6 months to 5 years) and 12 were short-term (6 weeks to 
6 months). The mean FEV1 was 50% in all but one trial 
in which the mean FEV1 was 75%. All trials were double-
blind while allocation concealment was adequate in 4 trials 
and not stated in 13 trials. Rates of patient withdrawal were 
available for all but one trial and ranged from 6% to 42%. 
Outcomes reported in these trials included all-cause mortality International Journal of COPD 2009:4 255
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in all 17 trials (n = 14,783), cardiovascular death in 12 trials 
(n = 12,376), myocardial infarction in 11 trials (n = 10,598) 
and stroke in 7 trials (n = 9251).
Inhaled anticholinergics significantly increased the risk 
of the composite outcome of cardiovascular death, myocar-
dial infarction, or stroke (1.8% vs 1.2% for controls; relative 
risk [RR] 1.58 [95% confidence interval (CI) 1.21–2.06] 
P  0.001). Inhaled anticholinergics increased the risk of 
myocardial infarction (1.2% vs 0.8% for controls; RR 1.53 
[95% CI 1.05–2.23] P = 0.03) and cardiovascular death 
(0.9% vs 0.5% for controls; RR 1.80 [95% CI 1.17–2.77] 
P = 0.008). Inhaled anticholinergics did not significantly 
increase the risk of stroke (0.5% vs 0.4% for controls; RR 
1.4 [95% CI 0.81–2.62]; P = 0.20). Inhaled anticholinergics 
did not significantly increase the risk of all-cause mortality 
(2.0% vs 1.6% for controls; RR 1.26 [95% CI 0.99–1.61] 
P = 0.06). In a sensitivity analysis limited to the 5 long-
term trials, the adverse effect of inhaled anticholinergics 
persisted (RR 1.73; P  0.001). There was no statistically 
significant increase in the risk of cardiovascular death, 
myocardial infarction, and stroke in a sensitivity analysis 
of the 12 short term trials (RR 1.16; P = 0.60). The adverse 
effect also persisted when the tiotropium trials (RR 2.12; 
P = 0.008) were separated from the ipratropium trials 
(RR 1.57; P = 0.02).
This meta-analysis has a number of methodological flaws 
which raise concerns about the validity of its conclusions.8 
The meta-analysis combined placebo-control studies with 
active-control studies. The numbers of patients and adverse 
clinical events in two of the trials included in the meta-
analysis were incorrectly reported. One study included in 
the meta-analysis was a duplicate publication of another 
study already included in the meta-analysis effectively 
leading to double counting of approximately 1000 patients 
in the analysis. Differences in patient exposure and discon-
tinuation rates were not accounted for in the meta-analysis. 
In most of the trials, a higher rate of premature treatment 
discontinuation occurred in the placebo groups compared to 
the active treatment. A substantial proportion of the overall 
number of patients included in the meta-analysis came from 
a single trial, the Lung Health Study (LHS). A retrospective 
analysis found that most of the cardiovascular deaths in the 
LHS occurred in patients who were non-compliant with their 
inhaled anticholinergic agent (ipratropium).
The earliest published study to suggest an adverse 
cardiovascular effect of inhaled anticholinergic agents in 
patients with COPD was the LHS.9 The LHS randomized 
5887 smokers who did not consider themselves ill but who 
had mild to moderate lung function impairment to one 
of three groups: (1) smoking cessation with ipratropium; 
(2) smoking cessation without ipratropium (placebo); 
and (3) usual care. Patients were followed for 5 years. 
There were no significant differences in mortality or hos-
pitalizations between the usual care group and either of 
the two smoking cessation groups. However, death due 
to cardiovascular disease was significantly greater in the 
smoking cessation plus ipratropium group compared to the 
smoking cessation plus placebo group (P = 0.027). Coronary 
heart disease deaths and the combination of fatal/nonfatal 
cardiovascular disease deaths were more frequent in the 
smoking cessation plus ipratropium group compared to the 
smoking cessation plus placebo group, but the differences 
between the groups did not reach statistical significance 
(P = 0.084 and P = 0.156). The statistical tests used were 
not adjusted for multiple tests and endpoints. In addition, 
the investigators were not able to demonstrate a convincing 
dose-effect relationship between ipratropium and the adverse 
cardiovascular outcomes. Most of the cardiovascular deaths 
occurring in the ipratropium group occurred among patients 
not compliant with their ipratropium. The investigators 
concluded that despite the higher rates of coronary and 
cardiovascular events and deaths in the ipratropium group, 
they were not able to prove or disprove that the difference 
in outcomes occurred due to a drug effect. They recommend 
that an adequately powered study be conducted to confirm or 
refute their findings and to investigate the possible mecha-
nisms of such an effect.
The LHS was obviously not able to determine a possible 
mechanism of the adverse cardiovascular effect of ipratro-
pium, but there was a higher frequency of hospitalizations 
for supraventricular tachycardia (SVT) in the smoking 
cessation plus ipratropium group compared to the smoking 
cessation plus placebo group. Even though the frequency 
of hospitalization for SVT was uncommon, a dose-effect 
relationship between ipratropium use and SVT requiring 
hospitalization was observed. Whether episodes of SVT 
or other arrhythmias not resulting in hospitalization led 
to a higher rate of myocardial ischemia or other adverse 
cardiovascular outcome in the LHS cannot be determined.
The Investigating New Standards for Prophylaxis in 
Reducing Exacerbations (INSPIRE) trial randomized 1323 
COPD patients to salmeterol/fluticasone 50/500 mg twice 
daily (n = 658) or to tiotropium 18 mg daily (n = 665).10 
The study was a 2-year multicenter, randomized, double-
blind, double-dummy trial with a primary efficacy endpoint 
of COPD exacerbations. Secondary endpoints included International Journal of COPD 2009:4 256
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spirometric parameters, health status measured by the 
St Georges Respiratory Questionnaire (SGRQ), and study 
withdrawal. All-cause mortality was an efficacy and safety 
endpoint. The study failed to demonstrate a significant 
difference in the rate of exacerbations between the study 
groups (62% for salmeterol/fluticasone and 59% for 
tiotropium). The probability of withdrawal from the study 
was 29% greater with tiotropium (279/665; 42%) than 
with salmeterol/fluticasone (232/658; 35%; P = 0.005). 
The SGRQ total score was statistically lower at 2 years in 
the salmeterol/fluticasone group compared to the tiotro-
pium group (-2.1 units; 95% CI 0.1–4.0; P = 0.038), but 
failed to reach the minimum clinically relevant difference. 
Mortality was significantly lower in the salmeterol/
fluticasone group (21/658; 3%) compared to the tiotro-
pium group (38/665; 6%; P = 0.032). Fatal cardiac events 
occurred in 1% (9/658) of the salmeterol/fluticasone 
group compared to 3% (19/665) in the tiotropium group. 
Pneumonia was more frequently reported in the salmeterol/
fluticasone group (8%) compared to tiotropium (4%). The 
hazard ratio for time to reported pneumonia was 1.94 
(95% CI 1.19–3.17; P = 0.008) with salmeterol/fluticasone 
compared to tiotropium.
Lee et al conducted a nested case control study in a cohort 
of patients identified through the US Veterans Administration 
(VA) healthcare system diagnosed with COPD between 
October 1, 1999 and September 30, 2003.11 The objective of 
the study was to examine the association between respiratory 
medication use and the risk of death (both cardiovascular 
and respiratory) in this large population of patients with 
recently diagnosed COPD. Identified patients were followed 
through September 30, 2004 using the VA administrative 
databases, the Centers for Medicare and Medicaid Services 
databases, and the National Death Index Plus database. 
Patients were eligible for inclusion in the study if they were 
given a diagnosis of COPD at two or more outpatient visits 
within 12 months or had a hospital admission with a primary 
diagnosis of COPD. Patients had to be at least 45 years old 
at the time of their COPD diagnosis, have used the VA 
health system for 1 year prior to that diagnosis, and received 
respiratory medications.
Case patients were all individuals that died during 
follow-up identified using the VA Vital Status database. Of 
these, 40% were randomly selected to determine a specific 
cause of death. The cause of death was determined using the 
National Death Index Plus data from the National Center 
for Health Statistics. Deaths were classified as respiratory, 
cardiovascular, respiratory or cardiovascular and any-cause 
mortality. Control patients were alive at the time of case 
deaths and individually matched at a rate of 10:1 on the basis 
of gender, age, region of the country, and year of diagnosis. 
Exposure to respiratory medications was defined as having 
received one or more of these medications in the 6-month 
period between COPD diagnosis and the study end date or 
death. Respiratory medications included inhaled corticoste-
roids, ipratropium, long-acting beta-agonists, theophylline, 
and short-acting beta-agonists.
The study included 32,130 case patients and 320,501 
control patients in the all-cause mortality analysis. Compared 
to no therapy or short-acting beta-agonists alone, both inhaled 
corticosteroids and long-acting beta-agonists were associ-
ated with reduced odds of all-cause mortality, ipratropium 
was associated with an increased risk of mortality, and 
theophylline had no significant effect on all-cause mortality. 
Adjusted (for covariates) odds ratios (ORs) for all-cause 
mortality were 0.80 (95% CI 0.78–0.83) for inhaled 
corticosteroids, 0.92 (95% CI 0.88–0.96) for long-acting 
beta-agonists, 1.05 (95% CI 0.99–1.10) for theophylline, 
and 1.11 (95% CI 1.08–1.15) for ipratropium.
In the cause specific mortality subgroup which included 
11,897 patients, 2405 case patients had respiratory deaths and 
3159 case patients had cardiovascular deaths. For respira-
tory deaths, theophylline significantly increased the risk of 
mortality (OR 1.71; 95% CI 1.46–2.00). Respiratory deaths 
were less frequent with inhaled corticosteroids (OR 0.88; 
95% CI 0.79–1.00) but this trend was not statistically signifi-
cant. Respiratory deaths were more frequent with long-acting 
beta-agonists (OR 1.12; 95% CI 0.97 to 1.30) and tiotro-
pium (OR 1.07; 95% CI 0.96–1.20), but these trends were 
also not significant. Inhaled corticosteroids (OR 0.8; 95% 
CI 0.72–0.88) significantly reduced the risk of cardiovascular 
deaths, while the effects of long-acting beta-agonists (OR 
0.97; 95% CI 0.84–1.11) and theophylline (OR 1.16; 95% 
CI 0.99–1.37) were not significantly significant. Ipratropium 
(OR 1.34; 95% CI 1.22–1.47) significantly increased the 
risk of cardiovascular death. When both cardiovascular and 
respiratory deaths were combined, inhaled corticosteroids 
(OR 0.86; 95% CI 0.8–0.93) significantly reduced mortality. 
Theophylline (OR 1.40; 95% CI 1.25–1.57) and ipratropium 
(OR 1.27; 95% CI 1.19–1.36) significantly increased com-
bined respiratory and cardiovascular mortality. The effect of 
long-acting beta-agonists (OR 0.98; 95% CI 0.89–1.09) on 
combined respiratory and cardiovascular mortality was not 
statistically significant.
Macie et al conducted a nested case-control analysis of 
subjects over the age of 35 years residing in the province International Journal of COPD 2009:4 257
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of Manitoba, Canada who saw a physician for bronchitis, 
asthma, or COPD during 1996 through 2000.12 Cases were 
patients hospitalized during that time frame for supraven-
tricular tachycardia, myocardial infarction, heart failure or 
stroke. Each case was matched according to gender, age and 
duration of insurance coverage with up to 10 controls that did 
not have that event. Exposure to respiratory drugs (inhaled 
beta-agonists, inhaled ipratropium, and inhaled corticoste-
roids) was documented in cases and controls. A conditional 
logistic regression was used in multivariate analysis which 
considered other respiratory drugs, respiratory diagnosis and 
visit frequency, and non-respiratory, non-cardiac comorbidi-
ties, and receipt of cardiovascular drugs.
In univariate analysis, beta-agonists, ipratropium, and 
inhaled corticosteroids were all associated with an increased 
frequency of cardiovascular hospitalizations. In the multi-
variate analysis, both beta-agonist and ipratropium use 
remained significantly associated with cardiac hospitaliza-
tions. However, the association between inhaled corticoste-
roids and cardiac hospitalizations was no longer significant. 
Inhaled corticosteroid use was actually associated with 
significantly fewer hospitalizations for supraventricular 
tachycardia, heart failure, and stroke. The use of cardiac 
drugs decreased the likelihood of hospitalization associated 
with beta-agonists and ipratropium. The addition of non-
respiratory and non-cardiac comorbidities did not affect 
the association between the bronchodilators and cardiac 
hospitalizations.
Guite et al followed a cohort of 2242 patients discharged 
from the hospital following an admission for asthma.13 
Eighty-five deaths occurred during a 3-year follow-up of 
this cohort and were compared with a randomly selected 
group of 122 survivors from the same cohort. Deaths due 
to asthma (OR 4.04; 95% CI 1.47–11.13), COPD (OR 7.75; 
95% CI 2.21–27.14), and cardiac causes (OR 3.55; 95% 
CI 1.05–11.94) were more common in patients prescribed 
ipratropium. Asthma deaths secondary due to ipratro-
pium remained significant even after adjustment for peak 
flow rates, presence or absence of COPD, cardiovascular 
co-morbidity, smoking, and age at onset of asthma. The use 
of inhaled corticosteroids was associated with a reduction 
in deaths due to asthma and COPD.
Ringbaek and Viskum identified a cohort of 827 patients 
with COPD and 273 patients with asthma.14 Over the course 
of follow-up, 65% of the COPD patients and 28% of the 
asthma patients died. Ipratropium use, after adjustment for 
FEV1, smoking, asthma medications, and cor pulmonale, 
was associated with a significant mortality risk in both 
COPD (RR 1.6; 95% CI 1.2–2.1) and asthma (RR 2.4; 95% 
CI 1.2–5.0).
Evidence that anticholinergics  
do not increase adverse 
cardiovascular outcomes
A pooled safety analysis published in 2006 included adverse 
event data from 19 randomized placebo-controlled clinical 
trials treating 4435 patients with tiotropium and 3384 patients 
with placebo.15 The average duration of drug therapy expo-
sure was 150 days with approximately two-thirds of patients 
receiving treatment for 6 months or less. The remaining 35% 
of patients received therapy for up to 12 months. These trials 
confirmed the most common side effects of tiotropium to be 
dry mouth and urinary retention. Urinary retention occurred 
with tiotropium at a rate 10 times greater than placebo. 
However, the overall frequency of urinary retention with 
tiotropium was observed in 13 cases out of 3521 patients 
treated compared to one case out of 2469 patients treated 
with placebo. The most common serious adverse event was 
COPD exacerbation which occurred at a significantly lower 
rate with tiotropium than with placebo. More serious out-
comes, such as all-cause mortality, cardiovascular mortality, 
and myocardial infarction did not occur more frequently with 
tiotropium. Compared to placebo, the relative risk of total 
mortality, cardiovascular mortality, and respiratory mortality 
with tiotropium were 0.76 (95% CI 0.5–1.16), 0.57 (95% CI 
0.26–1.26), and 0.71 (95% CI 0.29–1.74), respectively.
Tiotropium was compared to placebo in 5993 patients 
followed for 4 years in the Understanding Potential Long-
Term Impacts on Function with Tiotropium (UPLIFT) trial.16 
Eligible patients had to have a clinical diagnosis of COPD, be 
40 years or older, have a smoking history of at least 10 pack-
years, a postbronchodilator FEV1 of 70% or less of predicted, 
and an FEV1 of 70% or less of the FVC. Patients with asthma, 
a history of pulmonary resection, use of supplemental oxygen 
for more than 12 hours per day, and a COPD exacerbation 
or respiratory infection in the 4 weeks prior to screening 
were excluded from the study. Patients were allowed to use 
previously prescribed respiratory medications other than 
anticholinergics. Any medication could be used during the 
management of an acute COPD exacerbation. Drug therapy 
used for smoking cessation was also allowed.
The two co-primary endpoints of the trial were the 
yearly rate of decline in the mean prebronchodilator and 
postbronchodilator FEV1 from day 30 of treatment until the 
end double-blind treatment with tiotropium and placebo. International Journal of COPD 2009:4 258
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Secondary outcomes included the rate of decline in the 
mean FVC and slow vital capacity (SVC), health-related 
quality of life measured by the SGRQ, COPD exacerba-
tions, COPD exacerbations resulting in hospitalization, and 
all-cause mortality and mortality due to lower respiratory 
conditions.
Patients were recruited from January 2003 through March 
2004 with follow-up completed in February 2008. A total 
of 5993 patients were randomized with 2987 assigned to 
tiotropium and 3006 assigned to placebo. A greater number 
of patients failed to complete at least 45 months of treatment 
in the placebo group (45%) compared to the tiotropium group 
(36%) (P  0.001). There were no significant differences 
in the baseline demographics and clinical characteristics 
between the two treatment groups.
There were no significant differences between treatment 
groups in the rate of decline in the FEV1 and FVC either 
before or after bronchodilation from day 30 to the end of 
the study. Tiotropium did significantly improve quality of 
life scores compared to placebo at all time points. A signifi-
cantly greater proportion of patients had an improvement of 
4 units or more in total SGRQ scores in the tiotropium group 
than in the placebo group at each annual follow-up interval. 
Tiotropium was associated with a significant delay in the 
time to the first exacerbation (16.7 months vs 12.5 months) 
compared to placebo. Tiotropium was also associated with 
a significant delay in the time to the first hospitalization for 
an exacerbation and the overall number of exacerbations 
compared to placebo. The total number of exacerbations 
leading to hospitalizations was infrequent and did not differ 
significantly between tiotropium and placebo.
Mortality data for patients with a follow-up through the 
active treatment period of 1440 days was available for 95% 
of patients. The hazard ratio for mortality through 1440 days 
was 087 (95% CI 0.76–0.99; P = 0.034). Mortality data for 
patients with a follow-up through the 1440 days of active 
treatment plus the 30 days of post-treatment follow-up (1470 
days) was available for 75% of patents. Intention-to-treat 
mortality for patients with a follow-up of 1470 days was 
14.9% in the tiotropium group and 16.5% in the placebo 
group (hazard ratio, 0.89; 95% CI 0.79–1.02). The relative 
risk for serious adverse cardiac events for tiotropium vs 
placebo was 0.84 (95% CI 0.73–0.98; P  0.05). The relative 
risk of congestive heart failure (RR 0.59; 95% CI 0.37–0.96) 
and myocardial infarction (RR 0.71; 95% CI 0.52–0.99) was 
also significantly lower with tiotropium compared to placebo. 
The relative risk of stroke in the tiotropium vs placebo groups 
was not significantly different (RR 0.95; 95% CI 0.70–1.29). 
Serious adverse lower respiratory adverse events were less 
frequent with tiotropium compared to placebo (RR 0.84; 95% 
CI 0.77–0.92; P  0.05). COPD exacerbations, dyspnea, and 
respiratory failure were all significantly less common with 
tiotropium than with placebo.
Oba et al reanalyzed the studies included in the meta-
analysis published by Singh et al incorporating the results 
of the UPLIFT study.8 These investigators also corrected 
the errors in the Singh meta-analysis previously described. 
In the updated meta-analysis, the composite risk of 
myocardial infarction, stroke, and cardiovascular death was 
no longer significant with the use of tiotropium compared to 
the control group (RR 1.00; 95% CI 0.88–1.13; P = 0.97). The 
composite risk remained significant for ipratropium compared 
to controls (RR 1.70; 95% CI 1.19–2.42; P = 0.003), but 
90% of this effect was secondary to the results of the LHS. 
In addition, when only long-term trials were analyzed, the 
association between tiotropium and the composite risk of 
adverse cardiovascular outcomes was no longer statistically 
significant (RR 1.00; 95% CI 0.88–1.1; P = 0.96).
Several other studies have examined the relationship 
between anticholinergic use and mortality in COPD patients. 
Salpeter et al conducted a meta-analysis of 22 randomized 
controlled trials on beta-agonist (both short- and long-acting) 
and anticholinergic use in patients with COPD published 
between 1966 and December 2005.17 A total of 15,276 
patients were included in these studies with a mean follow-up 
of 20 months and a mean study size of 694 patients. A total 
of 7 trials compared inhaled anticholinergics with placebo, 
13 trials compared beta-agonists with placebo, and 7 trials 
compared anticholinergics with beta-agonists. Compared to 
placebo, anticholinergics reduced the risk of severe exacerba-
tions by 33% (RR 0.67; 95% CI 0.53–0.86) and respiratory 
deaths by 73% (RR 0.27; 95% CI 0.09–0.81). Compared with 
placebo, beta-agonists did not significantly reduce severe 
exacerbations (RR 1.08; 95% CI 0.61–1.95) and significantly 
increased the risk of respiratory deaths (RR 2.47; 95% CI 
1.12–45). When anticholinergics were compared to beta-
agonists, beta-agonist use was associated with an excess risk 
of exacerbation requiring study withdrawal (RR 2.02; 95% 
CI 1.39–2.93) and an excess risk of exacerbation requiring 
hospitalization (RR 1.95; 95% CI 1.06–3.59). As only two 
of the seven comparative trials reported mortality, conclu-
sions about relative mortality risk between anticholinergics 
and beta-agonists could not be reached.
Rodrigo et al also conducted a meta-analysis of random-
ized controlled trials comparing long-acting beta-agonists 
against either placebo or anticholinergic inhalers.18 Studies International Journal of COPD 2009:4 259
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had to include patients older than 35 years of age with a 
diagnosis of COPD (bronchitis or emphysema) who received 
a long-acting beta-agonist alone or in combination with 
an inhaled corticosteroid for at least 1 month in duration. 
Studies had to report the frequency of COPD exacerbations 
resulting in study withdrawal or hospitalization, all-cause 
mortality, and respiratory mortality. Secondary outcomes 
included changes in FEV1 and the SGRQ and the need for 
rescue bronchodilator. A total of 88 studies were identified 
of which 27 studies met the inclusion criteria. A total of 
20,527 patients were included in these studies. Compared 
to placebo, long-acting beta-agonists significantly reduced 
the relative risk of severe exacerbations (RR 0.78; 95% CI 
0.67–0.91). Compared to placebo, long-acting beta-agonists 
had no significant effect on the relative risk of respiratory 
deaths (RR 1.09; 95% CI 0.45–2.64). Addition of inhaled 
corticosteroids to long-acting beta-agonists reduced the 
risk of respiratory death compared to beta-agonists alone 
(RR 0.35; 95% CI 0.14–0.93). Compared to placebo, 
long-acting beta-agonists demonstrated significant benefits 
regarding airflow limitation, health-related quality of life, and 
use of rescue medications. In a limited number of studies, 
tiotropium significantly decreased the incidence of severe 
COPD exacerbations compared to long-acting beta-agonists 
(RR 0.52; 95% CI 0.31–0.87).
A population-based cohort study was conducted in 3 
counties in Denmark which used a National Health Service 
to provide medical care to its residents.19 Patients over 40 
years of age hospitalized for COPD between 1/1/1977 to 
12/21/2003 were identified. Cox regression was used to com-
pute incidence rate ratios (RR) and 95% CI for hospitalization 
and death between 1/1/2002 and 12/31/2003 associated with 
tiotropium use compared to periods of nonuse, controlling 
for a variety of confounders. A total of 2870 tiotropium 
users and 7733 non-users were identified with an average 
follow-up of 18 to 24 months. The relative risk for total and 
cause-specific hospitalizations was not increased during 
tiotropium use except for COPD hospitalizations (RR 1.52; 
95% CI 1.29–1.79). Total and cause-specific mortality was 
not significantly increased during tiotropium use.
A retrospective cohort study was performed using linked 
data from the Canadian Institute for Health Information, the 
Ontario Drug Benefit Program, the Ontario Health Insurance 
Plan, and the Ontario Registered Persons database to evaluate 
the effect of ipratropium on mortality rates in patients over 
the age of 65 years discharged from the hospital with a diag-
nosis of  COPD or asthma between 4/1/1992 and 3/31/1997.20 
A total of 32,292 patients were included in the analysis of 
which 49% received ipratropium within 90 days of discharge. 
After adjustment for age, gender, and other comorbidities, 
there was no significant association between the use of ipratro-
pium and mortality (RR 1.03; 95% CI 0.98–1.08) in patients 
with COPD. There was, however, a significant increase in 
the risk of mortality associated with the use of ipratropium 
(RR 1.24; 95% CI 1.11–1.39) in patients with asthma.
A cohort comparison using The Health Information 
Network in the United Kingdom (UK THIN) compared 
the risk of mortality and respiratory and cardiac adverse 
events in patients using tiotropium compared to patients 
using a long-acting beta-agonist during the time period from 
November 2002 until June 2004.21 The study population was 
not restricted to COPD. A total of 1061 tiotropium users 
and 1801 long-acting beta-agonist users were identified and 
followed for an average of 5 months. Total mortality and most 
cardiac event rates were not significantly different between 
the two treatment groups. There was, however, a significant 
decrease in the risk of heart failure among tiotropium users 
(HR 0.65; 95% CI 0.29–1.51) compared to long-acting beta-
agonists. The risk of respiratory events (COPD exacerbations 
and pneumonia) was not significantly different between the 
treatment groups. There was, however, a significant reduc-
tion in the risk of asthma exacerbations among tiotropium 
users (HR 0.41; 95% CI 0.26–0.64) compared to long-acting 
beta-agonist users.
Commentary
Evidence-based guidelines are only as good as the evidence 
used to support their recommendations. The strongest 
available evidence is randomized controlled trials that have 
adequate power to detect significant differences in the out-
comes they seek to evaluate. An inherent disadvantage of 
controlled trials is that they limit inclusion to patients with 
minimal comorbidities and other confounding characteristics. 
They also typically include patients who by definition are 
compliant. In other words, patients enrolled in controlled 
trials may not be representative of patients actually treated in 
a “real world” setting. Another major limitation of random-
ized controlled trials in COPD is the failure to collect out-
come data on a strict intention-to-treat basis. In many COPD 
trials, patients’ study participation ends when the study inter-
vention ends. When strict intention-to-treat data analysis is 
used, an important number of adverse cardiac and respiratory 
events occur after study treatment discontinuation. In one trial 
analyzed by Kesten et al premature treatment discontinua-
tion occurred in a substantially greater number of placebo 
patients compared to the active comparator (tiotropium).22 International Journal of COPD 2009:4 260
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If outcomes were limited to only those occurring during 
treatment, the results would have found a higher incidence 
of adverse clinical events in the active treatment group 
compared to placebo. By using strict intention-to-treat with 
follow-up for the pre-specified time period, patients receiv-
ing tiotropium actually had a significantly lower incidence 
of adverse clinical outcomes compared to placebo.
Other evidence which may be considered in the develop-
ment of treatment guidelines include meta-analyses, observa-
tional (cohort or case-control) studies, and consensus opinion 
or standards of care. None of these methodologies carry the 
weight upon which a class I treatment recommendation can 
be based. In addition, these methodologies cannot be used 
to prove or disprove hypotheses. A meta-analysis, when 
conducted properly, can only be used to generate a hypothesis. 
There are several examples of meta-analyses which indicated 
effectiveness of a particular treatment which was subsequently 
disproved by an adequately powered controlled trial.23,24
There have been 15 publications that have evaluated an 
association between inhaled anticholinergics and cardiovas-
cular safety in patients with COPD (Table 1). The number 
of publications observing an adverse cardiovascular effect 
of inhaled anticholinergics is roughly equal to the number of 
studies failing to document the association. Unfortunately, 
the quality of the evidence evaluating the cardiovascular 
risk of inhaled anticholinergic agents in patients with COPD 
is generally poor. Only three of the 15 publications were 
randomized controlled trials while the remaining studies 
included 5 meta-analyses, 2 case-control studies, and 5 cohort 
observations.
The ultimate question is why there is such wide disparity 
in the findings among the published data concerning the car-
diovascular risk of inhaled anticholinergic agents in patients 
with COPD. In general, case-control and cohort trials are 
limited by their inability to control for baseline differences 
among treatment groups with regard to smoking history, 
lung function, and disease severity. Dose-effect relation-
ships linking anticholinergic use with adverse cardiovascular 
outcomes are difficult to establish in these studies due to the 
inefficient and crude measures used to establish adherence 
to assigned drug regimens.
Meta-analyses, although methodologically more robust 
than case-control or cohort observations because they pool 
the results of randomized controlled trials, have significant 
Table 1 Publications evaluating the association between inhaled anticholinergics and adverse cardiovascular outcomes
Positive association between anticholinergics and adverse  
cardiovascular outcomes




Study design Drug evaluated Author Year 
published







Ipratropium vs placebo Oba8 2008 Meta-analysis re-analysis of 
Singh7 meta-analysis












Kesten15 2006 Pooled safety analysis Tiotropium vs 
placebo
Singh7 2008 Meta-analysis Ipratropium or 
tiotropium vs placebo  
or LABA or LABA-ICS
Salpeter17 2006 Meta-analysis Ipratropium or 
tiotropium vs 
LABA or LABA-ICS
Lee11 2008 Nested case  
control
Ipratropium vs LABA, 
ICS or theophylline
rodrigo18 2007 Meta-analysis Ipratropium or 
tiotropium vs 
LABA or LABA-ICS
Macie12 2008 Nested case 
control
Ipratropium vs  
LABA or ICS
de Luise19 2007 Observational cohort Tiotropium
Guite13 1999 Observational  
cohort
Ipratropium vs  
LABA or ICS
Sin20 2000 Observational cohort Ipratropium
ringback14 2003 Observational  
cohort
Ipratropium vs  
LABA or ICS
Jara21 2007 Observational cohort Tiotropium vs 
LABA
Abbreviations: LABA, long-acting beta-agonist; ICS, inhaled corticosteroid.International Journal of COPD 2009:4 261
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limitations. The major limitation of  the meta-analyses evaluating 
the relationship between anticholinergic use and cardiovascu-
lar risk is the exclusion of a large number of trials solely on the 
basis that cardiovascular endpoints were not reported. In the 
meta-analysis conducted by Singh et al, 71 of the 103 studies 
considered for inclusion were ultimately excluded because 
cardiovascular endpoints were not reported.7 This is also 
true for the meta-analyses that failed to establish a relation-
ship between anticholinergic use and adverse cardiovascular 
events. Another limitation of the published meta-analyses is 
that cardiovascular events reported in the pooled studies were 
not adequately adjudicated by a safety and data monitoring 
board. The primary endpoints of the included studies were 
outcomes other than mortality. Reporting of adverse cardio-
vascular outcomes may have inherently been incomplete or 
inaccurate.
Ultimately, adequately powered randomized controlled 
trials with adjudication of cardiovascular events are needed 
to assess the cardiovascular safety of anticholinergic agents in 
patients with COPD. Three randomized controlled trials have 
evaluated the cardiovascular safety of anticholinergic agents 
in patients with COPD.9,10,16 The first randomized controlled 
trial assessing the cardiovascular risk of an inhaled anti-
cholinergic in patients with mild to moderate lung function 
impairment was the LHS published in 2002.9 As previously 
discussed, the LHS observed a weak relationship between 
assignment to ipratropium use and a higher risk of death 
and hospitalization secondary to cardiovascular disease. The 
failure to adjust the observed P values for multiple com-
parisons and to establish a dose-effect relationship between 
ipratropium use and cardiac mortality prevented the LHS 
investigators from reaching the conclusion that ipratropium 
was absolutely associated with an adverse effect on cardio-
vascular mortality.
Both of the remaining randomized controlled trials 
evaluating the cardiovascular safety of anticholinergic agents 
included tiotropium (Table 2). The UPLIFT trial was an 
adequately designed randomized placebo-controlled trial 
evaluating the effect of tiotropium on the rate of decline 
of FEV1 in patients with moderate-to-very severe COPD.16 
Tiotropium failed to slow the rate of decline in spirometric 
parameters, but did significantly improve quality of life 
scores, reduce the frequency of exacerbations, prolong the 
time to the first hospitalization for an exacerbation, and 
reduce the frequency of respiratory failure. Tiotropium 
was associated with a lower all-cause mortality rate, but 
this failed to reach statistical significance (HR 0.89; 95% 
CI 0.79–1.02) when follow-up through 1470 days was 
used. The incidence rate of serious cardiac (RR 0.84; 
95% CI 0.73–0.98) and lower respiratory (RR 0.84; 95% 
CI 0.77–0.94) adverse events was significantly lower with 
tiotropium than placebo.
Table 2 Comparisons of randomized controlled trials of bronchodilators in patients with COPD
INSPIRE10 UPLIFT16 TORCH25
SFC TIO TIO PLAC SFC S F PLAC
enrolled 658 665 2987 3006 1523 1521 1534 1524
withdrew 232 (35%) 279 (42%) 1099 (37%) 1358 (45%) 522 (34%) 561 (37%) 587 (38%) 673 (44%)
Duration 2 years 4 years 3 years
Age 64 65 64 64 65 65 65 65
% men 81 84 75 74 76 76 75 76
Post-bronch  
Fev1
39 39 47 47 44 44 44 44
Smokers 38 38 29 30 43 43 43 43
Smoking history  
(pack-year)
41.3 39.5 49 48 49 49 49 47
SGrQ 48.6 49.1 45.7 46.0 49 50 49 49
On ICS 48 51 62 62 47 45 47 51
All cause  
mortality
21 (3%) 38 (6%) 14.9% 16.5% 12.6% 13.5% 16.0% 15.2%
Cardiac  
death
9 (1%) 19 (3%) 26 (0.9%) 32 (1.1) 4% 3% 4% 5%
History of  
Cv disease
9 (3%) 24 (8%) Nr Nr Nr Nr Nr Nr
Abbreviations: SFC, salmeterol plus fluticasone combination;   TIO, tiotropium; PLAC, placebo; S, salmeterol; F, fluticasone; ICS, inhaled corticosteroids; SGRQ, St George’s 
respiratory Questionnaire.International Journal of COPD 2009:4 262
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The INSPIRE trial, an adequately designed 2-year trial 
primarily designed to compare to the impact of the combi-
nation of salmeterol/fluticasone and tiotropium on COPD 
exacerbations, found that neither treatment was superior 
with regard to the frequency of exacerbations (Table 2).10 
The salmeterol/fluticasone combination was associated with 
significantly lower rates of study withdrawal (29% less) and 
all-cause mortality (52% reduction) compared to tiotropium. 
In patients with baseline cardiovascular disease, cardiac death 
occurred in 3% of the salmeterol/fluticasone group and 8% 
of the tiotropium group. The reduction in cardiovascular 
mortality was offset in part by a 2-fold increase in the risk 
of pneumonia in the salmeterol/fluticasone group (8%) com-
pared to the tiotropium group (4%). The INSPIRE trial was 
not designed as a mortality trial, lacked adequate adjudication 
of fatal outcomes, and lacked a full intention-to-treat analysis 
of the data. The failure to follow patients after treatment 
discontinuation and a potential bias introduced during the 
run-in period render the mortality results of the INSPIRE 
trial difficult to interpret.
The Towards a Revolution in COPD Health (TORCH) 
trial was a 3 year randomized placebo-controlled trial 
comparing fluticasone alone, salmeterol alone or their 
combination in 6112 COPD patients (Table 2).25 Although 
this trial did not include an anticholinergic agent, the results 
are illustrative of the potential difficulty in demonstrating 
a mortality benefit of drug therapy in patients with COPD. 
The primary outcome of the trial was all-cause mortality 
comparing the combination of salmeterol plus fluticasone 
against placebo. Compared to placebo, the combination 
treatment group reduced exacerbations, improved health 
status, and improved spirometric measures. All-cause 
mortality was 12.6% in the combination group, 13.5% in 
the salmeterol monotherapy group, 15.2% in the placebo 
group, and 16.0% in the fluticasone group. The hazard ratio 
for the combination group was 0.825 (95% CI 0.68 to 1.00) 
compared to placebo (P = 0.052). Hence, no randomized 
trial has been able to demonstrate a mortality benefit of drug 
therapy in patients with COPD.
The results of the placebo-controlled UPLIFT and 
TORCH trials suggest that similar outcomes, including 
all-cause mortality, are achieved when patients with 
COPD are treated either with tiotropium or a combination 
of salmeterol/fluticasone. The INSPIRE trial, although 
methodologically flawed, suggests a significant mortality 
benefit of salmeterol/fluticasone over tiotropium. Are the 
results of the INSPIRE trial, the only randomized controlled 
trial that clearly favors the use of salmeterol/fluticasone 
over tiotropium, of sufficient weight to influence clinical 
decisions concerning the use of tiotropium? Are the results 
of the INSPIRE trial of sufficient weight to change the 
current treatment guidelines which do not make a specific 
recommendation for a specific bronchodilator?
Evaluation of the study designs, patient populations, and 
results of the UPLIFT, TORCH, and INSPIRE offer little 
evidence to suggest that any of these three trials were seri-
ously flawed. One difference among these three trials that 
has raised some questions is the reported absolute mortality 
rate. The INSPIRE trial reported on overall mortality rate of 
about 4.5% with a 2-year follow-up, while the TORCH and 
UPLIFT trials reported overall mortality rates of approxi-
mately 13% to 16% with 3- to 4-year follow-ups. The severity 
of illness of enrolled patients do not appear to be dramati-
cally different, although the study with the lowest mortality 
(INSPIRE) had the lowest mean baseline post-bronchodilator 
FEV1 (38% vs 44%–47%). One major limitation of each of 
these trials is the failure to report the incidence of baseline 
major co-morbidities. The numbers of patients with prior 
coronary heart disease and other co-morbidities is not 
disclosed. It is interesting to note that in the INSPIRE trial, 
mortality results for patients with a history of cardiac disease 
are reported, but the incidence of cardiac disease at baseline 
is unknown. It is clear given the disparate mortality outcomes 
between the three randomized trials that attempts to compare 
studies enrolling different patient populations and reach valid 
conclusions based on those comparisons is futile.
Following the FDA’s early communication and the pub-
lication of the meta-analysis by Singh et al the American 
College of Chest Physicians convened a task force of pulmo-
nologists with expertise on the use of inhaled bronchodilators 
in patients with COPD. The task force reached four areas of 
agreement. (1) Smoking cessation remains the only treat-
ment proven to slow the progression of COPD in all stages 
and reduced the risk of death from cardiovascular disease. 
(2) More patients with severe COPD die from cardiovas-
cular disease (heart attack or stroke) than from respiratory 
failure. (3) All of the risks, benefits, and costs of the inhaled 
medications used for COPD need to be assessed when they 
are prescribed and at each follow-up visit. Decisions about 
changes in the use of inhaled anticholinergics in patients with 
COPD should consider the patient’s symptoms, comorbidi-
ties, patient comfort level, and potential benefit versus risk. 
(4) Prospective, adequately powered randomized clinical 
trials, designed and monitored by the NHLBI and FDA, 
should be conducted to provide more evidence regarding 
the safety of tiotropium. The goal of these studies should International Journal of COPD 2009:4
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be to determine the subsets of patients with COPD at the 
highest risk of adverse cardiovascular events. The studies 
should include adjudication of the cardiovascular events and 
represent the patients who are treated with these drugs in a 
real world setting.
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